Swot Analysis Of Novartis Pharma
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Swot Analysis Of Novartis Pharma as PDF for free.
More details
- Words: 1,519
- Pages: 15
Human Resource Management
HUMAN RESOURCE MANAGEMENT Project SUBMITTED TO:
SIR .YASIR AFTAB FAROOQI SUBMITTED BY:
Gulam Abbass
08011420-012 Group #2
MBA
2nd
UNIVERSITY OF GUJRAT
Human Resource Management
Human Resource Management
History Novartis pharmaceutical is established in 1996.The history of Novartis traces back to three companies Geigy Pharmaceutical ➢ Ciba pharmaceutical ➢ Sandoz pharmaceutical ➢
Giegy whose origin goes back to the middle of the 18th century. CIBA founded around 1859and Sandoz established in 1886 In1970 CIBA and Giegy merged .the newly created CIBA-Geigy ltd and Sandoz continued to follow separate path for two and half decades In1996 Sandoz and CIBA-Geigy joined to form Novartis pharmaceutical.
Head Office Novartis International AG CH-4002 Basel Switzerland Tel: +41 61 324 11 11 Fax: +41 61 324 80 01
Head office in Pakistan Novartis Pharma (Pakistan) LTD. 15 West Wharf Road, Karachi 74000, Sindh, Pakistan Phone: 9221-2313389 / 2316286 / 2313387 / 2313390 Fax: 9221-2310241
Human Resource Management
Mission: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.
Vision: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.
Sector Head Farhan Baider Malik 15 West Wharf Road, Karachi 74000, Sindh, Pakistan Phone: 9221-2313389 / 2316286 / 2313387 / 2313390 Fax: 9221-2310241
Managers Khalid Ashraf
(National Sales Manager)
Moiz Haider
(Brand Manager)
Zubair Ahmed
(Training Manager)
Ali Imran
(Human Resource Manager)
Moin Khan
(Factory head)
Regional Sales Managers Tuyyab Nazir Mujeeb Alam M Shakeel
Lahore Multan Karachi
Human Resource Management
Arshad Iqbal
Islamabad
Zonal Sales Managers Lahore Muhammad Zeeshan Altaf M. Sohail Aslam
Faisalabad M. Ejaz Qamer Shahzad Ali
Islamabad Naveed Basheer Ikram Ulah Khan M.Usman
Multan Shahzad Jamil Ghazanfar Aziz Ghauri Qamar Zaman
Gujranwala Abaid ur Rehman
Sukhar Imtiaz Soomro Abdul Hameed
Karachi Faizan Ur Rehman Syed Ather Hussain Asif Ali Khan
Human Resource Management
Hyderabad Jawaid Jabbar Syed Shoaib Hussain Naveed Farooque
Peshawar Noorullah Jan Inayat Ullah Khan Afridi
Designation of contacted person Ali Imran ACCA, MBA (HRM) (Human Resource Manager) Phone: 9221-2313388 / 2316289 Fax: 9221-2310242
Human Resource Management
Company Competitors
Human Resource Management
PRODECTS ➢ CAC-1000 ➢ CAC 1000 Plus ➢ CAC 1000 Plus Pineapple ➢ VEG 20mg ➢ T DAY ➢ SPASMO CIBALGIN ➢ CALCIUM SAN. SYP.120ML ➢ TRIAMINIC SYP. 60ML ➢ TRIAMINIC SYP. 120ML ➢ TRIAMINIC-E SYP. 60ML ➢ TRIAMINIC-DM 60ML ➢ Triaminic Cold & Allergy ➢ Triaminic Cough ➢ Triaminic Chest Congestion ➢ Triaminic Cough, Cold & Fever ➢ TANDEGYL D ➢ TANDEGYL SYRUP ➢ NEO-INTESTOPAN 60 ml ➢ QALSAN MINT ➢ QALSAN MIX ➢ CALCIUM+VIT. C A50X10ML ➢ SANCOS ➢ TANDEGYL T-30 ➢ TANDEGYL-DS T-10 ➢ TANDEGYL INJ. A50X2ML ➢ LAMISIL CREAM ➢ LAMISIL SPRAY
Human Resource Management
➢ NEO-INTESTOPAN T 250 ➢ OPTALIDON T-200
SWOT ANALYSIS
Strengths • • • • •
• • •
Market Leader Strong CNS image of Novartis Strong brand image-Heritage, Valuation Strong rapport with KOLs High acceptance of carbamazepine as an anti epileptic FDA approved Effective in multiple indications First line, first choice therapy
Opportunities • • • •
Weaknesses
High growth rate of the market More doctors particularly GPs are diagnosing epilepsy High treatment gap Lot of potential in different indications (PDN)
• • • •
Only one formulation is available No formulation for children Mostly under dosage is recommended Lack of resources to tap attractive opportunities
Threats • • • •
High SoV of competition Increasingly high acceptance of valproates Increased penetration of low cost Generics in institutions Epival has many galenical forms
Human Resource Management
•
New Molecules are high cost & with low safety profile
WEAKNESSES AND THREATS
Threats
•
• •
• • •
•
Existing Threat: High Share of Voice of competition. Increased penetration of low cost Generics in institutions Rapid growth of below the line and direct to consumer advertising Increasingly high acceptance of valproates Epival has many galenical forms Potential Threat: Introduction of new molecules Compliance is low
• •
Introduction of new molecules Compliance is low
Weaknesses • • • •
Only one formulation is available No formulation for children Mostly under dosage is recommended Lack of resources to tap attractive opportunities
Proposed Strategies 1. Formulation should be introduced for children and young adults. 2. Promotional Strategy to create awareness and increase mind share 3. Promote KOLs to increase the number of patients 4. Optimize the loyalty base of Tegral users 5. Switch Epival users to Tegral 6. Low dosage range extension
Human Resource Management •
Entry/exit into the Industry: Increase in number of neuroscience competitive
should be introduced 7. In regions other than Karachi, Lahore and Peshawar, distribution should be made more extensive to increase availability. More agents should be contacted 8. Management should strategize their aims to retain their sales force through benefit planning and incentives.
products. Consumers have been offered more and more choices.
WEAKNESSES AND OPPURTUNITIES
Opportunities
Weaknesses • • • •
Proposed Strategies •
• • • •
High growth rate of the market More doctors particularly GPs are diagnosing epilepsy High treatment gap Lot of potential in different indications
Only one formulation is available No formulation for children Mostly under dosage is recommended Lack of resources to tap attractive opportunities
• •
Conduct seminars and workshops to train GPs about Epilepsy and the usage of Tegral. Treatment gap should be reduced by awareness programs in rural areas. Cost - plus pricing should be practiced for new molecules exposures and regulations for safety should be
Human Resource Management
•
(PDN) New Molecules are high cost & with low safety profile
•
enhanced Local firms desirous of export but lacking necessary export structure
Strengths
STRENGTHS AND OPPURTUNITIES
• • • • •
• • •
Market Leader Strong CNS image of Novartis Strong brand image-Heritage, Valuation Strong rapport with KOLs High acceptance of carbamazepine as an anti epileptic FDA approved Effective in multiple indications First line, first choice therapy
Human Resource Management
Proposed Strategies Opportunities
• •
• • • • •
•
Capitalize on strong CNS franchise – build further rapport with KOLs Patient Evaluation Programs: For KOL Development KEEP (Key Experts Evaluation Programs)Painful Diabetic Neuropathies for 30 Physicians BOC - 2 Programs for 30 Doctors each for PDN Epilepsy Project
High growth rate of the market More doctors particularly GPs are diagnosing epilepsy High treatment gap • Lot of potential in different indications (PDN) • New Molecules are high cost & with low safety profile - CME Programs for Family Physicians (Epilepsy) - Epilepsy Camps (28 camps organized so far) •
Neuroscience Summit: Patient Evaluation Program for major Brands of Neuroscience, Total 35 Top KOLs from Neurology & Psychiatry
Strengths
STRENGTHS AND THREATS
• • • • • • • •
Market Leader Strong CNS image of Novartis Strong brand image-Heritage, Valuation Strong rapport with KOLs High acceptance of carbamazepine as an anti epileptic FDA approved Effective in multiple indications First line, first choice therapy
Human Resource Management
Threats •
• •
• • •
• •
Existing Threat: High Share of Voice of competition. Increased penetration of low cost Generics in institutions Rapid growth of below the line and direct to consumer advertising Increasingly high acceptance of valproates Epival has many galenical forms Potential Threat: Introduction of new molecules Compliance is low Entry/exit into the Industry: Increase in number of neuroscience competitive products. Consumers have been offered more and more choices.
Proposed Strategies • • • • • • • • • • • •
Build further rapport with KOLs Exploit on strong CNS franchise Patient Evaluation Programs should be conducted for KOL Development Own distribution structure of Tegral, measuring highest in clinical evaluation, effectiveness & safety Summits of KOLs for top brands in neuroscience to increase share of voice Focus to minimize substitution. More Focus on RMOS Better Awareness of Epilepsy Project Refine Advertisement media More sustained branding Powerful message delivery Monitor promotion in different indications
Suggestions ➢ They should provide proper training to employees so that they can easily understand the current technology. ➢ They should organize some seminars. ➢ HR should interact with labor as well as office staff. ➢ HR should look after the problems of each employee and try to solve according his own experience. ➢ They should provide some extra facilities such as bonuses, increments, visits to outside country so that they don’t think switch off.
Human Resource Management
➢ HR should develop ethical practices. For this purpose they should set some rules and regulations. ➢ Right person for the right job. ➢ Looking for better ways of working after results in new ways of doing things. ➢ HR manager must be prepared to train employees in the new process and help them train new level that may be associated with the “new. Improved” operations.
HUMAN RESOURCE MANAGEMENT Project SUBMITTED TO:
SIR .YASIR AFTAB FAROOQI SUBMITTED BY:
Gulam Abbass
08011420-012 Group #2
MBA
2nd
UNIVERSITY OF GUJRAT
Human Resource Management
Human Resource Management
History Novartis pharmaceutical is established in 1996.The history of Novartis traces back to three companies Geigy Pharmaceutical ➢ Ciba pharmaceutical ➢ Sandoz pharmaceutical ➢
Giegy whose origin goes back to the middle of the 18th century. CIBA founded around 1859and Sandoz established in 1886 In1970 CIBA and Giegy merged .the newly created CIBA-Geigy ltd and Sandoz continued to follow separate path for two and half decades In1996 Sandoz and CIBA-Geigy joined to form Novartis pharmaceutical.
Head Office Novartis International AG CH-4002 Basel Switzerland Tel: +41 61 324 11 11 Fax: +41 61 324 80 01
Head office in Pakistan Novartis Pharma (Pakistan) LTD. 15 West Wharf Road, Karachi 74000, Sindh, Pakistan Phone: 9221-2313389 / 2316286 / 2313387 / 2313390 Fax: 9221-2310241
Human Resource Management
Mission: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.
Vision: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.
Sector Head Farhan Baider Malik 15 West Wharf Road, Karachi 74000, Sindh, Pakistan Phone: 9221-2313389 / 2316286 / 2313387 / 2313390 Fax: 9221-2310241
Managers Khalid Ashraf
(National Sales Manager)
Moiz Haider
(Brand Manager)
Zubair Ahmed
(Training Manager)
Ali Imran
(Human Resource Manager)
Moin Khan
(Factory head)
Regional Sales Managers Tuyyab Nazir Mujeeb Alam M Shakeel
Lahore Multan Karachi
Human Resource Management
Arshad Iqbal
Islamabad
Zonal Sales Managers Lahore Muhammad Zeeshan Altaf M. Sohail Aslam
Faisalabad M. Ejaz Qamer Shahzad Ali
Islamabad Naveed Basheer Ikram Ulah Khan M.Usman
Multan Shahzad Jamil Ghazanfar Aziz Ghauri Qamar Zaman
Gujranwala Abaid ur Rehman
Sukhar Imtiaz Soomro Abdul Hameed
Karachi Faizan Ur Rehman Syed Ather Hussain Asif Ali Khan
Human Resource Management
Hyderabad Jawaid Jabbar Syed Shoaib Hussain Naveed Farooque
Peshawar Noorullah Jan Inayat Ullah Khan Afridi
Designation of contacted person Ali Imran ACCA, MBA (HRM) (Human Resource Manager) Phone: 9221-2313388 / 2316289 Fax: 9221-2310242
Human Resource Management
Company Competitors
Human Resource Management
PRODECTS ➢ CAC-1000 ➢ CAC 1000 Plus ➢ CAC 1000 Plus Pineapple ➢ VEG 20mg ➢ T DAY ➢ SPASMO CIBALGIN ➢ CALCIUM SAN. SYP.120ML ➢ TRIAMINIC SYP. 60ML ➢ TRIAMINIC SYP. 120ML ➢ TRIAMINIC-E SYP. 60ML ➢ TRIAMINIC-DM 60ML ➢ Triaminic Cold & Allergy ➢ Triaminic Cough ➢ Triaminic Chest Congestion ➢ Triaminic Cough, Cold & Fever ➢ TANDEGYL D ➢ TANDEGYL SYRUP ➢ NEO-INTESTOPAN 60 ml ➢ QALSAN MINT ➢ QALSAN MIX ➢ CALCIUM+VIT. C A50X10ML ➢ SANCOS ➢ TANDEGYL T-30 ➢ TANDEGYL-DS T-10 ➢ TANDEGYL INJ. A50X2ML ➢ LAMISIL CREAM ➢ LAMISIL SPRAY
Human Resource Management
➢ NEO-INTESTOPAN T 250 ➢ OPTALIDON T-200
SWOT ANALYSIS
Strengths • • • • •
• • •
Market Leader Strong CNS image of Novartis Strong brand image-Heritage, Valuation Strong rapport with KOLs High acceptance of carbamazepine as an anti epileptic FDA approved Effective in multiple indications First line, first choice therapy
Opportunities • • • •
Weaknesses
High growth rate of the market More doctors particularly GPs are diagnosing epilepsy High treatment gap Lot of potential in different indications (PDN)
• • • •
Only one formulation is available No formulation for children Mostly under dosage is recommended Lack of resources to tap attractive opportunities
Threats • • • •
High SoV of competition Increasingly high acceptance of valproates Increased penetration of low cost Generics in institutions Epival has many galenical forms
Human Resource Management
•
New Molecules are high cost & with low safety profile
WEAKNESSES AND THREATS
Threats
•
• •
• • •
•
Existing Threat: High Share of Voice of competition. Increased penetration of low cost Generics in institutions Rapid growth of below the line and direct to consumer advertising Increasingly high acceptance of valproates Epival has many galenical forms Potential Threat: Introduction of new molecules Compliance is low
• •
Introduction of new molecules Compliance is low
Weaknesses • • • •
Only one formulation is available No formulation for children Mostly under dosage is recommended Lack of resources to tap attractive opportunities
Proposed Strategies 1. Formulation should be introduced for children and young adults. 2. Promotional Strategy to create awareness and increase mind share 3. Promote KOLs to increase the number of patients 4. Optimize the loyalty base of Tegral users 5. Switch Epival users to Tegral 6. Low dosage range extension
Human Resource Management •
Entry/exit into the Industry: Increase in number of neuroscience competitive
should be introduced 7. In regions other than Karachi, Lahore and Peshawar, distribution should be made more extensive to increase availability. More agents should be contacted 8. Management should strategize their aims to retain their sales force through benefit planning and incentives.
products. Consumers have been offered more and more choices.
WEAKNESSES AND OPPURTUNITIES
Opportunities
Weaknesses • • • •
Proposed Strategies •
• • • •
High growth rate of the market More doctors particularly GPs are diagnosing epilepsy High treatment gap Lot of potential in different indications
Only one formulation is available No formulation for children Mostly under dosage is recommended Lack of resources to tap attractive opportunities
• •
Conduct seminars and workshops to train GPs about Epilepsy and the usage of Tegral. Treatment gap should be reduced by awareness programs in rural areas. Cost - plus pricing should be practiced for new molecules exposures and regulations for safety should be
Human Resource Management
•
(PDN) New Molecules are high cost & with low safety profile
•
enhanced Local firms desirous of export but lacking necessary export structure
Strengths
STRENGTHS AND OPPURTUNITIES
• • • • •
• • •
Market Leader Strong CNS image of Novartis Strong brand image-Heritage, Valuation Strong rapport with KOLs High acceptance of carbamazepine as an anti epileptic FDA approved Effective in multiple indications First line, first choice therapy
Human Resource Management
Proposed Strategies Opportunities
• •
• • • • •
•
Capitalize on strong CNS franchise – build further rapport with KOLs Patient Evaluation Programs: For KOL Development KEEP (Key Experts Evaluation Programs)Painful Diabetic Neuropathies for 30 Physicians BOC - 2 Programs for 30 Doctors each for PDN Epilepsy Project
High growth rate of the market More doctors particularly GPs are diagnosing epilepsy High treatment gap • Lot of potential in different indications (PDN) • New Molecules are high cost & with low safety profile - CME Programs for Family Physicians (Epilepsy) - Epilepsy Camps (28 camps organized so far) •
Neuroscience Summit: Patient Evaluation Program for major Brands of Neuroscience, Total 35 Top KOLs from Neurology & Psychiatry
Strengths
STRENGTHS AND THREATS
• • • • • • • •
Market Leader Strong CNS image of Novartis Strong brand image-Heritage, Valuation Strong rapport with KOLs High acceptance of carbamazepine as an anti epileptic FDA approved Effective in multiple indications First line, first choice therapy
Human Resource Management
Threats •
• •
• • •
• •
Existing Threat: High Share of Voice of competition. Increased penetration of low cost Generics in institutions Rapid growth of below the line and direct to consumer advertising Increasingly high acceptance of valproates Epival has many galenical forms Potential Threat: Introduction of new molecules Compliance is low Entry/exit into the Industry: Increase in number of neuroscience competitive products. Consumers have been offered more and more choices.
Proposed Strategies • • • • • • • • • • • •
Build further rapport with KOLs Exploit on strong CNS franchise Patient Evaluation Programs should be conducted for KOL Development Own distribution structure of Tegral, measuring highest in clinical evaluation, effectiveness & safety Summits of KOLs for top brands in neuroscience to increase share of voice Focus to minimize substitution. More Focus on RMOS Better Awareness of Epilepsy Project Refine Advertisement media More sustained branding Powerful message delivery Monitor promotion in different indications
Suggestions ➢ They should provide proper training to employees so that they can easily understand the current technology. ➢ They should organize some seminars. ➢ HR should interact with labor as well as office staff. ➢ HR should look after the problems of each employee and try to solve according his own experience. ➢ They should provide some extra facilities such as bonuses, increments, visits to outside country so that they don’t think switch off.
Human Resource Management
➢ HR should develop ethical practices. For this purpose they should set some rules and regulations. ➢ Right person for the right job. ➢ Looking for better ways of working after results in new ways of doing things. ➢ HR manager must be prepared to train employees in the new process and help them train new level that may be associated with the “new. Improved” operations.
Related Documents
Swot Analysis Of Novartis Pharma
June 2020 2
Novartis Analysis
November 2019 13
Swot Analysis Of Nalco
July 2020 24
Swot Analysis Of Ufone
December 2019 36
